Stocks and Investing Stocks and Investing
Wed, November 27, 2019

Gena Wang Upgraded (BMRN) to Buy and Held Target at $98 on, Nov 27th, 2019


Published on 2024-10-26 18:40:35 - WOPRAI, Gena Wang
  Print publication without navigation


Gena Wang of Barclays, Upgraded "BioMarin Pharmaceutical Inc." (BMRN) to Buy and Held Target at $98 on, Nov 27th, 2019.

Gena has made no other calls on BMRN in the last 4 months.



There are 3 other peers that have a rating on BMRN. Out of the 3 peers that are also analyzing BMRN, 0 agree with Gena's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Gena


  • Mohit Bansal of "Citigroup" Maintained at Strong Buy with Decreased Target to $95 on, Wednesday, October 30th, 2019
  • Michelle Gilson of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $108 on, Monday, October 28th, 2019
  • Liana Moussatos of "Wedbush" Maintained at Buy with Increased Target to $152 on, Friday, October 25th, 2019
Contributing Sources